Regdanvimab

立即咨询

Regdanvimab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2444308-95-4

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议

产品名称

CT-P59

产品介绍

Regdanvimab (CT-P59) 是一种人单克隆抗体，靶向SARS-CoV-2刺突蛋白的受体结合域，阻断与ACE2的相互作用以防止病毒进入。Regdanvimab 可用于 COVID-19 的研究。

生物活性

Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain ofSARS-CoV-2spike protein, blocking interaction withACE2for viral entry. Regdanvimab can be used for the research of COVID-19^[1].

IC₅₀& Target

SARS-CoV-2, ACE2^[1]

体外研究
(In Vitro)

Regdanvimab (CT-P59) (0-1000 ng/mL; 72 h) can neutralize Gamma, Delta and Epsilon variants with IC₅₀s of 161.5-1237 ng/mL^[1].

体内研究
(In Vivo)

Regdanvimab (CT-P59) (5-80 mg/kg; i.p.; single dose) 可以降低小鼠 Gamma 和 Delta 株的病毒负担^[1]。

Animal Model:	hACE2 transgenic (TG) mice inoculated with Gamma or Delta variant^[1]
Dosage:	5, 20, 40, and 80 mg/kg
Administration:	Intraperitoneal injection, 8 h post-inoculation, single dose
Result:	Delayed body weight loss and showed a statistically significant difference compared to the placebo group. Prevented the weight loss of the mice infected with Delta variant. Significantly inhibited the virus replication in the respiratory tract.

CAS 号

2444308-95-4

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.